Baolingbao Biology Co (002286) Fair Value & Analysis

Healthcare · CN · Market cap 3.5B CNY

A solid business, currently priced close to our fair value.

What matters now

• The price sits close to our fair value, market and models broadly agree here, little valuation tension.
• A fairly wide model range (¥4.61 to ¥10.39) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.

How to read this chart

60‑month range ¥4.72 – ¥14.89 · fair‑value band ¥4.61 – ¥10.39 · the ¥8.00 price screens above the ¥7.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Baolingbao Biology Co (002286) currently trades at ¥8.00, while our model-based Fair Value estimate is ¥7.79, implying the stock looks roughly 2.6% fairly valued today. The Quality Score stands at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Baolingbao Biology Co generated revenue of 2.8B CNY at a net margin of 5.5%. Revenue grew 9.2% year over year. It earns a return on equity of 7.0%. Net debt stands at 6.4M CNY. Fundamentals as of Jul 22, 2026

Our scenario range runs from ¥4.61 (bear case) to ¥10.39 (bull case); at ¥8.00, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 40% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -3%, 002286 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (¥7.08) versus Dividend Discount (¥1.27). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Baolingbao Biology Co.,Ltd. researches and develops, manufactures, and sells a range of functional sugars in China. The company offers prebiotics, such as isomaltooligosaccharides, galactooligosaccharides, fructooligosaccharides, bagasse trisaccharides, and xylooligosaccharides; sugar alcohols and new sugar source products, including erythritol, trehalose, …

Full company description

Baolingbao Biology Co.,Ltd. researches and develops, manufactures, and sells a range of functional sugars in China. The company offers prebiotics, such as isomaltooligosaccharides, galactooligosaccharides, fructooligosaccharides, bagasse trisaccharides, and xylooligosaccharides; sugar alcohols and new sugar source products, including erythritol, trehalose, crystalline fructose, alodonose, and maltose; dietary fiber products comprising polydextrose and resistant dextrin; modified, waxy maize, and corn starch products; starch sugar products, including oligomaltose, fructose syrup, solid corn syrup, maltodextrin, and glucose syrup; and animal nutrition products comprising baolekang and fubaokang. Its products are used in various applications, such as dairy products, drinks, snacks, health products and dietary supplements, candy, special food items, chemicals for daily use, and animal nutrition. The company was founded in 1997 and is based in Yucheng, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Baolingbao Biology Co reported revenue of ¥2.8B in FY2025 versus ¥2.8B in FY2021, a compound −0.1%/yr. Reported net income was ¥151M in FY2025, compounding −7.0%/yr from FY2021.

Watch 002286: get an alert when its fair value changes →

Peer Group

Biotechnology · 603 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Biotechnology median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.